Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APLT 
Applied Therapeutics Inc (APLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: APLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.62
1 Year Target Price $5.62
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.34% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.84M USD | Price to earnings Ratio - | 1Y Target Price 5.62 |
Price to earnings Ratio - | 1Y Target Price 5.62 | ||
Volume (30-day avg) 4 | Beta 1.87 | 52 Weeks Range 0.29 - 10.62 | Updated Date 06/30/2025 |
52 Weeks Range 0.29 - 10.62 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -41030.57% |
Management Effectiveness
Return on Assets (TTM) -65.3% | Return on Equity (TTM) -83.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 370987 | Price to Sales(TTM) 172.99 |
Enterprise Value 370987 | Price to Sales(TTM) 172.99 | ||
Enterprise Value to Revenue 1.4 | Enterprise Value to EBITDA -9.71 | Shares Outstanding 141576000 | Shares Floating 117715803 |
Shares Outstanding 141576000 | Shares Floating 117715803 | ||
Percent Insiders 5.49 | Percent Institutions 83.05 |
Analyst Ratings
Rating 2 | Target Price 5.62 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Applied Therapeutics Inc
Company Overview
History and Background
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2016. It focuses on developing novel therapies for unmet medical needs in rare, debilitating, and life-threatening diseases.
Core Business Areas
- Drug Development: Development of small molecule drugs targeting specific diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Shoshana Shendelman is the CEO and President. The company has a standard organizational structure with departments focused on research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- Govorestat: A central nervous system penetrant Aldose Reductase Inhibitor (ARI) currently undergoing trials for treatment of Sorbitol Dehydrogenase (SORD) Deficiency, and Galactosemia. The market is niche but addresses a critical unmet need. Competitors include companies developing gene therapies and other novel treatments for rare metabolic disorders.
- Cafenoresone: A novel PPARu03b3 agonist being developed for Diabetic Cardiomyopathy (DCM). It is currently in Phase 3 trials. Competitors include existing heart failure medications and other companies developing therapies for DCM.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition. Companies like Applied Therapeutics focus on niche markets with high unmet needs.
Positioning
Applied Therapeutics is positioned as a developer of therapies for rare and underserved diseases. Their competitive advantage lies in their targeted approach and novel drug candidates.
Total Addressable Market (TAM)
The TAM varies depending on the specific disease target. SORD Deficiency affects a small population, while Diabetic Cardiomyopathy has a larger patient base. The company is positioned to capture a significant share of these niche markets if their therapies are approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Single clinical failure can reduce the stock value significantly
Opportunities
- Regulatory approvals
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory changes
Competitors and Market Share
Key Competitors
- VRTX
- BMY
- LLY
Competitive Landscape
Applied Therapeutics faces competition from established pharmaceutical companies with greater resources and expertise. However, its focus on niche markets and novel drug candidates provides a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by pipeline advancements and stock price appreciation. Requires Data Updates.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary but generally positive if drugs are approved.
Recent Initiatives: Focusing on completing pivotal trials for Govorestat and Cafenoresone, and advancing other pipeline programs.
Summary
Applied Therapeutics is a clinical-stage biopharmaceutical company with promising drug candidates targeting rare diseases. The company's success hinges on the outcome of its clinical trials and regulatory approvals. While it faces financial challenges common to biotech companies, its focus on unmet needs and innovative therapies offers growth potential. Investors should closely monitor clinical trial results and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Applied Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data accuracy is not guaranteed. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-05-14 | Interm CEO, CFO, Principal Financial Officer & Director Mr. Les D. Funtleyder | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | |
Full time employees 36 | |||
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.